Business
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership.
About this update from Fifty 1 Labs Inc.
[{"type":"text","content":"\r\n\r\n \r\n \r\n Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership\r\n \r\n \r\n\r\n\r\nFifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership\r\nPioneering a New Era in Healthcare: AI-Driven Innovation Unlocks Transformative Therapies and Drives Path to $50M Valuation\r\n\r\n\r\n\r\n\r\n\r\nSEATTLE, July 10, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, LLC, a wholly owned subsidiary of Fifty 1 Labs, Inc. (OTC: FITY), in collaboration with premier academic institutions including Stanford University, Duke University, McMaster University (Canada), and global partners, proudly announces the successful completion of the REVIVE Adaptive Platform Trial (NCT06128967). This historic Phase III, multicenter, adaptive, randomized, double-blind, placebo-controlled trial, the largest and most rigorous Long COVID study to date, marks a pivotal milestone in addressing a global health crisis affecting approximately 400 million people and 15% of COVID-19 survivors, with an estimated economic burden exceeding USD 1 trillion, annually. Powered by Fifty1 AI Labs' proprietary AI platform and aligned with Fifty 1 Labs, Inc.'s ambitious Game Plan to lead the $320.6 billion functional medicine market and achieve a $50 million valuation, the REVIVE Trial positions the company as a trailblazer in AI-driven drug repurposing and precision medicine, delivering transformative therapies and substantial shareholder value. A Landmark Achievement in Long COVID Research and Functional Medicine The REVIVE Trial is the first adaptive platform trial to demonstrate a clear treatment benefit for Long COVID, leveraging repurposed medicines to address this debilitating condition. This breakthrough aligns seamlessly with Fifty 1 Labs, Inc.'s vision to revolutionize healthcare through AI-driven drug repurposing and functional medicine, targeting high-growth areas like preventative healthcare within the $5.68 trillion biotech market (CAGR 13.8%, Precedence Research). By addressing Long COVID's complex symptoms through innovative, data-driven therapies, Fifty1 AI Labs is advancing personalized medicin...